1	Longitudinal analysis of the gut microbiome in adolescent patients with				
2	anorexia nervosa: microbiome-related factors associated with clinical				
3	outcome				
4	Nadia Andrea Andreani ^{a,b,*,#} , Arunabh Sharma ^{c,*} , Brigitte Dahmen ^d , Hannah E.				
5	Specht ^d , Nina Mannig ^d , Vanessa Ruan ^d , Lara Keller ^d , John F. Baines ^{a,b} , Beate				
6	Herpertz-Dahlmann ^d , Astrid Dempfle ^c , Jochen Seitz ^d				
7	^a Max Planck Institute for Evolutionary Biology, August-Thienemann-Str. 2, 24306 Plön,				
8	Germany; ^b Section of Evolutionary Medicine, Institute for Experimental Medicine, Kiel				
9	University, Arnold-Heller-Str. 3, 24105 Kiel, Germany; ^c Institute of Medical Informatics and				
10	Statistics, Kiel University, Kiel, Germany; ^d Department of Child and Adolescent Psychiatry,				
11	Psychosomatics and Psychotherapy, University Hospital, RWTH Aachen University, Aachen,				
12	Germany				
13	*These authors contributed equally to present study				
14	[#] This author serves as corresponding author: Nadia Andrea Andreani, Max Planck Institute for				
15	Evolutionary Biology, August-Thienemann-Str. 2, 24306 Plön, Germany				
16	andreani@evolbio.mpg.de				
17	Author ORCID:				
18	Nadia Andrea Andreani: 0000-0003-0330-9874				
19	Arunabh Sharma: 0000-0001-7808-0942				
20	Brigitte Dahmen				
21	Hannah E. Specht				
22	Note This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.				

- 23 Vanessa Ruan
- 24 Lara Keller
- 25 John F. Baines
- 26 Beate Herpertz-Dahlmann: 0000-0001-8450-3323
- 27 Astrid Dempfle: 0000-0002-2618-3920
- 28 Jochen Seitz: 0000-0002-0110-7980

Longitudinal analysis of the gut microbiome in adolescent patients with anorexia nervosa: microbiome-related factors associated with clinical outcome.

33 There is mounting evidence regarding the role of gut microbiota in anorexia nervosa (AN). Previous studies have reported that patients with AN show 34 dysbiosis compared to healthy controls (HCs); however, the underlying 35 36 mechanisms are unclear, and data on influencing factors and longitudinal course of microbiome changes are scarce. Here, we present longitudinal data of 57 37 adolescent inpatients diagnosed with AN at up to nine time points (including a 1-38 year follow-up examination) and compare these to up to six time points in 34 39 HCs. 16S rRNA gene sequencing was used to investigate the microbiome 40 composition of fecal samples, and data on food intake, weight change, hormonal 41 recovery (leptin levels), and clinical outcomes were recorded. Differences in 42 43 microbiome composition compared to HCs were greatest during acute starvation and in the low-weight group, while diminishing with weight gain and especially 44 45 weight recovery at the 1-year follow-up. Illness duration and prior weight loss were strongly associated with microbiome composition at hospital admission, 46 whereas microbial changes during treatment were associated with kilocalories 47 consumed, weight gain, and hormonal recovery. The microbiome at admission 48 49 was prognostic for hospital readmission, and a higher abundance of Sutterella was associated with a higher body weight at the 1-year follow-up. Identifying 50 these clinically important factors further underlines the potential relevance of gut 51 microbial changes and may help elucidate the underlying pathophysiology of gut-52 brain interactions in AN. The characterization of prognostically relevant taxa 53 could be useful to stratify patients at admission and to potentially identify 54 55 candidate taxa for future supplementation studies aimed at improving AN 56 treatment.

57 Keywords: microbiota, anorexia nervosa, eating disorder, gut-brain axis,

adolescents, longitudinal study, weight-recovered patients, low-weight patients,

59 illness duration, long-term follow-up.

60 Introduction:

Anorexia nervosa (AN) is the third most common chronic disease in adolescence and the deadliest of all psychiatric diseases, with a standardized mortality rate 5-10 times higher than that in healthy controls (Arcelus et al., 2011; Bulik et al., 2019; Carr et al., 2016). AN is characterized by insufficient energy intake, low body weight, body image distortion, and fear of gaining weight. However, the underlying pathophysiology is poorly understood. Treatment includes weight restoration and psychotherapy but often remains insufficient, and there is a high rate of relapse (Herpertz-Dahlmann et al., 2021).

The gut microbiome is increasingly recognized as an influencing factor for energy extraction from food and weight regulation, as well as having an influence on the brain and behavior via the gut-brain axis. Interest in the role of the microbiome in psychiatric diseases is on a steep rise (Hills et al., 2019; Santacroce et al., 2021; Wu et al., 2021).

Animal models of AN show intestinal dysbiosis (Breton et al., 2021; Trinh et al., 2021) and point to the potentially important role of gut microbes in the pathogenesis and course of AN. Offspring of gnotobiotic mice transplanted with AN patients' stool showed reduced weight gain, as well as increased anxiety and obsessiveness, which are common comorbidities in AN (Hata et al., 2019). Moreover, directly transplanted "humanized" mice with AN patients' stool showed lower weight gain than HC-transplanted animals when fed a calorie-reduced diet (Fan et al., 2023).

Patient studies during acute starvation have confirmed intestinal dysbiosis, albeit with
heterogeneous results (Di Lodovico et al., 2021; Mack et al., 2016; Seitz et al., 2020). Very
few longitudinal studies have reported residual changes after short-term weight restoration
(Fouladi et al., 2022; Mack et al., 2016; Schulz et al., 2021). However, to our knowledge, no
study has followed patients after hospital discharge or tracked them for longer than 6 months.
Thus, it remains unclear whether the microbiome normalizes over a longer period after weight

gain. Moreover, hospital food can act as a potential confounder when comparing the microbiome to healthy controls who eat at home. Furthermore, while studies have identified clinical factors to be associated with the microbiome in AN cross-sectionally (Borgo et al., 2017; Di Lodovico et al., 2021; Fan et al., 2023; Mack et al., 2016; Yuan et al., 2022), there are no reports of longitudinal associations, and only one study has attempted to predict the clinical course from microbiota alterations found at admission in AN (Schulz et al., 2021).

91 Here, we present the first longitudinal investigation, including data collected at the 1year follow-up after admission, to investigate the degree of microbial normalization in 92 93 individuals with AN classified as weight-recovered and on a home-based diet (thus making hospital food-related effects less likely). Up to nine time points were sampled to determine 94 which clinical factors influence the microbiome in patients with AN, including illness duration, 95 weight loss, and body weight at admission, and the potentially differential influence of 96 nutritional, weight-related, and hormonal restitution during the treatment process. Furthermore, 97 this longitudinal study allowed us to test whether microbiota can help predict weight 98 development and relapse. 99

100 **Results**

Fifty-six patients aged between 12 and 20 years and diagnosed with AN or atypical AN 101 102 (one patient) according to DSM-5 were admitted to the specialized inpatients eating disorder unit at the Department for Child and Adolescent Psychiatry of the RWTH Aachen University 103 Hospital. Stool samples and clinical data were collected at up to eight timepoints (T0-T7) 104 during inpatient stay with one additional sampling at follow-up appointment (T8) 1 year after 105 admission (Fig 1). After discharge, eight patients were re-admitted to the department within 106 one year due to weight loss. At follow-up assessments, patients were classified as having low 107 weight or still weight recovered based on the age- and sex-specific percentile of the Body Mass 108 Index (BMI) based on the German Health Interview and Examination Survey for Children and 109

110 Adolescents (KiGGS; Neuhauser et al., 2013). Specifically, individuals with a BMI lower than the 15th percentile (P<15) were classified as low weight, while individuals with a BMI greater 111 than or equal to the 15th percentile ($P \ge 15$) were classified as weight-recovered (chosen with a 112 safety margin of 5 percentile points towards the official definition of "underweight" at the 10th 113 BMI percentile). Inpatient treatment included weight rehabilitation with incremental increases 114 in kilocalories (Fig 2A) and weight gain until achieving individually determined target weight, 115 116 based on weight before the onset of the illness, hormonal recovery, and menstruation state (Fig 2B). Additionally, serum leptin concentration was measured at admission, discharge, and 117 118 follow-up appointments to test for hormonal recovery (Fig 2C). Thirty-four age-matched healthy controls (HCs; aged between 14 and 19 years) were sampled at six time-matched time 119 points (Fig 1). A summary of the clinical characteristics of the patients included in this study 120 121 is presented in Tab 1.

Inpatient treatment aimed at body weight rehabilitation as well as at improving eating behavior, as evidenced by the increase in BMI, percentage of Expected Body Weight (%EBW), and BMI-SDS, despite these measures being still different from the HC group (Tab 1). After 1 year, patients with a BMI at or above the 15th percentile (classified as weight-recovered) had clinical characteristics that were more similar to the age-matched HC group (Tab 1 and Fig 2).

Differences in gut microbiome between AN patients and healthy controls and longitudinal changes in the gut microbiome

A total of 22,848,660 16S rRNA sequence reads (63,645.29 ± 25,857.34 per sample, mean ±
SD) were generated from the DNA extracted from 359 stool samples at nine time points, as
specified in the Patients and Methods section and summarized in Tab S1_Sheet1.

After clustering with >97% similarity and rarefying 10,400 reads, 1,011 bacterial
amplicon sequence variants (ASVs) were identified, which spanned 12 different phyla, 79

different families, and 212 different genera. Tab S1_Sheet2 shows the total ASV counts andtaxonomic classification.

The gut microbiome of adolescent patients with AN was significantly different from 136 that of HCs during acute starvation at admission (Fig 3A/B, Tab S1_Sheet3). The microbiome 137 changed over the course of treatment but remained at least partly different from HCs at all time 138 points, even in those patients who were classified as weight-recovered at 1-year follow-up [T8] 139 140 $1y(P \ge 15)$]. Fig 3A shows the average relative abundances of 23 genera that were significantly different in pairwise comparisons of patients at admission, discharge, and follow-up 141 142 assessment, as well as in comparison to HCs at admission and 1-year follow-up (Wilcoxon signed-rank, fdr corrected p < 0.05; see the following paragraphs and Tab S1 for details). 143 Similarly, Fig 3B shows the shift in the microbiome composition in patients at all time points 144 available between admission and follow-up, as seen in longitudinal multilevel partial least 145 squares-discriminant analysis (mPLS-DA). 146

Longitudinal changes in alpha-diversity using Shannon and Chao1 indices are displayed 147 in Fig 3C. Both values were lowest in the two follow-up groups. Alpha-diversity indices of 148 fecal samples of low-weight patients at the 1-year follow-up were significantly different 149 compared to their values at admission and discharge time points and to HCs (Fig 3C, left, and 150 Tab S1_Sheet3). Additionally, the Chao1 index showed a reduction during inpatient treatment, 151 with significant differences when comparing patients at admission, discharge, and 1-year 152 153 follow-up. Importantly, both values showed significant or trend-level reductions in weightrecovered patients after 1 year in comparison to HCs, hinting at a lack of complete microbiome 154 recovery even in the weight-recovered subgroup (Fig 3C, right, and Tab S1_Sheet3). 155

To test the hypothesis that fecal microbiomes of patients with AN have a distinctive composition both cross-sectionally and longitudinally, we used a combination of univariate and multivariate approaches by comparing the microbiome of patients at different taxonomic

levels (from phylum- to ASV-level) with the microbiome of the HC groups (Fig 4A, and Tab 159 S1 Sheet4). PERMANOVA based on Bray-Curtis dissimilarities showed significant 160 differences in overall microbiome composition between patients with AN at admission and 161 HCs at baseline from family- to ASV-level (PERMANOVA p=0.0007 to 0.005, Fig 4A). PLS-162 DA showed that the genera Legionella, Dialister, Ruminococcaceae UCG-003 and 163 *Limnobacter* contributed most strongly to this differentiation, all of which were less abundant 164 165 in AN (Fig 4B and Fig S1A). Univariate comparisons between the two groups in individual taxa at the family- to ASV-level identified differences in the genera Erysipelotrichaceae UCG-166 167 003, Dialister, Family XIII group, Anaerostipes, Ruminococcaceae UCG-003, Anaerotruncus and Erysipelatoclostridium (Mann-Whitney-U-test multiple comparisons fdr corrected 168 *p*=0.0032 to 0.048, Tab S1_Sheet 5). 169

170 At T7 discharge, PLS-DA and PERMANOVA based on Bray-Curtis dissimilarities showed a significant difference between AN and HC fecal microbiome only at the ASV-level 171 (PERMANOVA *p*=0.007; Fig 4A, 4C, Tab S1_Sheet4, and Fig S1B), suggesting that inpatient 172 treatment reduces the differences between these two groups. The Wilcoxon rank sum test 173 identified five ASVs as being differentially abundant in patients at discharge compared with 174 HCs. These were the ASV322 (uncl. Erysipelotrichaceae UCG-003), ASV524 (uncl. 175 Lachnospiraceae), ASV578 and ASV798 (both uncl. Ruminococcaceae UCG-005) and 176 ASV363 (uncl. *Dialister*) with a fdr corrected p=0.03 to 0.04 [Mann-Whitney-U-test, Tab 177 S1_Sheet 6]. 178

At T8_1-year follow-up, the microbiome of subgroups of patients with AN and HCs were again significantly different at all taxonomic levels (PERMANOVA p=0.005 to 0.03, Fig 4A, Tab S1_Sheet4), as also visible in the PLS-DA graph in Fig 4C and Fig S1C, which depict the main differences among low-weight, recovered patients, and the HC group. However, separately comparing low-weight patients [T8 1y(P<15)] with the HCs at 1 year showed

comparable differences to admission at lower taxonomic levels (PERMANOVA p=0.001 to 184 <0.001), with differences being recorded at the phylum-, class- and order-levels (Fig 4A, Fig 185 S1D, and Tab S1_Sheet4). On the other hand, differences between recovered AN patients [T8 186 $1y(P \ge 15)$] and HCs were much smaller (PERMANOVA p=0.063) at the ASV-level when 187 performing a PERMANOVA on Bray-Curtis dissimilarity distances (Fig 4A, Fig S1E and Tab 188 S1 Sheet4). Univariate comparisons of low-weight patients with HCs revealed some major 189 190 differences at all taxonomic levels (from phylum- to genus- level), with corrected *p*-values between 0.008 and 0.04 (Mann-Whitney-U-test, Tab S1_Sheet 7). The genera [Eubacterium] 191 192 hallii group and Agathobacter were significantly more abundant in HCs than in low-weight patients. Interestingly, these differences were not observed when comparing recovered 193 individuals with the HC group, with only one unique and rare taxon (family 194 195 Desulfovibrionaceae) significantly more abundant in recovered patients (Mann-Whitney-Utest fdr corrected p=0.02; Tab S1 Sheet 8). 196

To understand the extent to which these changes are due to inpatient treatment, weight 197 gain, and remission and to study the potentially confounding role of different foods in the 198 hospital and at home, we performed pairwise investigations by applying multivariate and 199 univariate approaches, comparing patients at admission, at discharge, and at the 1-year follow-200 up appointment. Inpatient treatment was associated with changes at all taxonomic levels 201 202 (change between admission and discharge; PERMANOVA p=0.003 to 0.01). However, 203 univariate analysis identified the genus Fusicatenibacter as a unique taxon that was significantly more abundant at discharge (Wilcoxon signed-rank test fdr corrected p=0.027; 204 Tab S1_Sheet 9). Interestingly, among low-weight patients, the overall microbiome 205 206 composition was significantly different between admission and 1-year follow-up, with PERMANOVA on Bray-Curtis dissimilarity showing significant *p*-values at all levels, 207 potentially due at least in part to hospital food being consumed at admission vs. home food at 208

follow-up (PERMANOVA p=0.0005 to 0.001; Fig 4A, and Tab S1_Sheet4). Specifically, lowweight patients showed a significant reduction in the relative abundance of the genera *Anaerostipes, Clostridium sensu stricto 1* and *Romboutsia* compared to the microbiome composition of these patients at admission (Wilcoxon signed-rank test corrected p-value= 0.02, Tab S1_Sheet 10). On the other hand, individuals who recovered at follow-up showed a surprisingly higher similarity between admission and follow-up, with significant p-values only at the genus- and ASV-level (Fig 4A and Tab S1_Sheet4).

Similarly, low-weight patients had a distinct microbiome at follow-up when compared 216 217 to the assessment at discharge (PERMANOVA p=0.006 to 0.001, Fig 4A, and Tab S1_Sheet4), while these differences were less marked when comparing recovered patients between follow-218 up and discharge, with a significant *p*-value of the PERMANOVA only at the ASV-level 219 220 (PERMANOVA p = 0.02). In low-weight patients, we observed 4 times higher abundance of the genus *Escherichia-Shigella* (Wilcoxon signed-rank test fdr corrected p = 0.04) and a 2 times 221 higher abundance of *Alistipes* (Wilcoxon signed-rank test fdr corrected p = 0.03) between 222 follow-up and discharge. 223

224 Clinical variables associated with microbiome composition

To investigate which clinical variables were associated with the overall microbiome 225 226 composition, we applied PERMANOVA analysis to the Bray-Curtis dissimilarity index. Analysis at admission revealed that illness duration (phylum-family level, PERMANOVA 227 p=0.011 to 0.022) and the amount of weight loss (class-genera level, PERMANOVA p=0.030228 to 0.047, Fig 5 and Tab S1_Sheet 13) were significantly associated with microbiome 229 composition. In contrast, BMI-SDS (PERMANOVA p=0.14 to 0.24), Kcal at admission 230 (PERMANOVA p=0.42 to 0.92), and leptin concentration (PERMANOVA p=0.26 to 0.84) 231 displayed little variability in the acute starvation phase and did not show a significant 232 association with microbiome composition at this time point. 233

Next, we performed a longitudinal PERMANOVA analysis, including genus data from 234 all nine time points. After correcting for laxative use, we found a significant association 235 between the gut microbiome and the amount of ingested Kcals (PERMANOVA p=0.003) and 236 BMI-SDS (PERMANOVA p=0.005). Even though these two variables are highly correlated, 237 they both showed independent contributions when combined in one model (PERMANOVA 238 p=0.03 for BMI-SDS; p=0.02 for Kcals, respectively). Leptin concentration was measured at 239 240 admission, discharge, and 1-year follow-up, and showed a significant association with the microbiome when analyzed alone (PERMANOVA p=0.02). When analyzed together, these 241 242 three potentially influencing factors (Kcal, BMI-SDS, and leptin) were strongly intercorrelated, so that only BMI-SDS and leptin at the trend-level showed independent contributions 243 (PERMANOVA *p*=0.023 to 0.054). 244

245 Prediction of hospital-readmission and BMI-SDS at 1-year follow-up based on baseline 246 microbiome data

PERMANOVA analysis of the whole microbiome community at admission revealed a 247 significant association with hospital readmission until the 1-year follow-up when considering 248 the data at admission at the ASV-level (p=0.04). The genera significantly associated with 249 hospital readmission were Ruminiclostridium 5 and Intestinibacter (p=0.006 and 0.03, 250 251 respectively); ASVs showing significant association with hospital readmission until the 1-year follow-up were ASV600 and ASV95 (p=0.0004 and p=0.02, both uncl. Subdoligranulum), 252 ASV666, and ASV83 (*p*=0.003 and *p*=0.008, both uncl. *Lachnospiraceae*), ASV 238 (*p*=0.01, 253 uncl. Clostridium sensu stricto), ASV19 (p=0.03, uncl. Ruminiclostridium) and ASV873 254 (p=0.03, uncl. Intestinibacter). There was no significant association between BMI-SDS at 255 T8 1 year follow-up and overall microbiome composition at baseline (all p>0.2). 256

Linear model analysis related to the abundance of specific taxa at baseline to BMI-SDS
at 1-year follow-up, while correcting for laxative use, illness duration, weight loss, and BMI-

SDS at admission, identified four genera (*Sutterella, Parasutterella, Lachnospiraceae FCS020 group*, and *Clostridium sensu stricto*, *p*=0.008 to 0.040; Fig 6, Tab S1_Sheet14) and four ASVs
(uncl. *Clostridium sensu stricto*, uncl. Bacteroides, uncl. *Alistipes*, uncl. *Parasutterella*, *p*=0.002 to 0.01, Fig 6, Tab S1_Sheet14) that were associated with the BMI-SDS at 1 year
follow-up.

264 **Discussion**

265 Our study presents the first longitudinal investigation of fecal microbial changes in patients with AN compared with age-matched healthy controls, including a 1-year follow-up. Our 266 results show that dysbiosis in acutely ill patients with AN is improved during inpatient 267 268 treatment and long-term weight recovery. The remaining microbiome alterations in the weight-269 recovered subgroup after 1 year compared to HCs were small but remained significant. The differences found in the low-weight group indicate that the disease itself is the main driver of 270 271 these microbiome differences and not the consequence of the consumption of hospital vs. home food. The up to nine assessment points sampled in this study allowed us to further elucidate 272 the clinical factors associated with these longitudinal microbial changes. We found that illness 273 duration and the amount of weight loss prior to admission were important for microbiome 274 composition at admission, in line with an extensive body of research showing their clinical 275 276 relevance as markers of disease severity. We also found that the kilocalories consumed, ensuing weight gain, and hormonal restitution were all clearly related to longitudinal microbiome 277 composition changes during the treatment process. These results indicate that starvation is a 278 279 major driving force for changes in the microbiome. These results further support previous clinical findings regarding the importance of nutritional restitution and reaching a sufficiently 280 high target weight. Finally, our longitudinal follow-up showed that the composition of 281 microbiota at admission can help predict relapse and that individual taxa were associated with 282 increased or decreased BMI-SDS at the 1-year follow-up. Importantly, a higher abundance of 283

Sutterella is indicative of a positive clinical outcome and thus qualifies as a potential probiotic target or supplement for future animal and human studies. These findings are in line with a potentially important or contributing role of the gut microbiome on clinical outcomes, at least as a factor in maintaining the disease, as suggested by animal studies.

288 Altered microbiome characteristics in patients with AN

Our data report a reduction in Shannon's and Chao 1 indices at 1-year follow-up, which were 289 290 slightly more marked in low-weight patients. We did not observe any significant change in alpha-diversity measures during inpatient treatment, as found by Kleiman et al. (2015); 291 however, the literature is heterogeneous regarding this point (Dhopatkar et al., 2023; Di 292 293 Lodovico et al., 2021; Garcia & Gutierrez, 2023). The reduction in alpha-diversity after 294 returning to a home environment could be associated with a change in diet, although this does not explain the newly appearing differences in the comparison with healthy controls. Most 295 296 likely, different underlying mechanisms overlap in influencing alpha-diversity at this point in time, including remaining differences in food choice, body weight, hormonal status, and 297 exercise, even in recovered patients with AN (Castro et al., 2021; Hübel et al., 2019). 298

Although the gut microbiome in patients with AN remained different from that in HCs 299 at all time points, the differences diminished with weight recovery and over time. At admission, 300 301 there were significant multivariate and univariate differences at different taxonomic levels, whereas after short-term weight recovery at discharge, only ASVs showed significant 302 differences. This is in line with previous studies suggesting that the composition of the gut 303 304 microbiome shifts during inpatient weight gain treatment (Fouladi et al., 2022; Kleiman et al., 2015; Mack et al., 2016; Schulz et al., 2021). The fact that patients with AN have a distinct 305 306 microbiome when compared to healthy individuals is in line with several studies that have focused on the fecal microbiome in adults (Borgo et al., 2017; Fan et al., 2023; Monteleone et 307

al., 2021), or the combination of both adolescents and adults combined (Mack et al., 2016;
Yuan et al., 2022).

One added value of our study was the presence of a long-term follow-up investigation 310 1 year after admission. Interestingly, the microbiome of weight-recovered individuals (i.e., 311 those who had a BMI at least greater than or equal to the 15th percentile) showed only small 312 differences from that of the HCs (univariate differences in Desulfovibrionaceae family, a trend 313 314 in the multivariate analysis and significant alpha-diversity differences). Importantly, as the target weight was determined at an individual level, many patients had a BMI higher than the 315 15th percentile (mean 29th percentile, range 15th-60th percentile) considered necessary for their 316 personal recovery. These results support the hypothesis of continuous recovery of the gut 317 microbiome with adequate weight increase and/or time. However, a complete recovery cannot 318 319 yet be concluded at the 1-year follow-up in weight-recovered patients. Further research is necessary to address this phenomenon, especially as the remaining differences in nutritional 320 uptake and the remaining lower body weight compared with HCs are common in this subgroup, 321 as noted above. Interestingly, the low-weight subgroup showed dramatic differences when 322 compared to controls again at the 1-year follow-up, ruling out a hospital vs. home food artifact 323 in previous comparisons of acutely ill (hospitalized) patients with AN and HCs at home. This 324 further underlines the importance of sustaining a healthy weight and, also for gut microbial 325 326 normalization.

At admission, *Dialister* was significantly less abundant in patients than in age-matched HCs (as also reported in Garcia-Gil et al., 2022 and Yuan et al., 2022); interestingly, this genus increased in abundance during inpatient treatment and was not significantly differentially abundant in any other pairwise comparisons. A large cohort study found a reduced abundance of this genus in people diagnosed with depression and major depressive disorder, suggesting a role for this taxon in contributing to the psychological signs associated with AN (Cheung et

al., 2019; Valles-Colomer et al., 2019). Another notable increase in *Escherichia* abundance 333 was observed between discharge and follow-up appointments in patients with insufficient 334 weight recovery. E. coli is a well-known producer of caseinolytic protease B (ClpB), a protein 335 involved in appetite regulation (Breton et al., 2021; Tennoune et al., 2014), and associated with 336 anxiety severity (Mason et al., 2020) and AN (Yuan et al., 2022). Remarkably, this genus 337 appears to be differentially abundant only in low-weight patients, suggesting its involvement 338 339 in the chronicity of the disease. Similarly, the genus Alistipes was significantly more abundant in these patients (on average twice as abundant as that at discharge). A member of Alistipes 340 341 (Alistipes ihumii) was isolated for the first time in 2014 from a patient with AN (Pfleiderer et al., 2014). Members of this genus are involved in anxiety and depression, as they have the 342 potential to degrade tryptophan, the precursor of serotonin (Garcia-Gil et al., 2022; Kaur et al., 343 2019; Parker et al., 2020), and have been reported to be increased in patients with AN when 344 compared to HCs (Di Lodovico et al., 2021; Prochazkova et al., 2021; Schulz et al., 2021). 345 Overrepresented taxa in low-weight patients also include the genus Anaerostipes, which was 346 found to be increased in anorexia nervosa, bulimia nervosa, and depression (Levrolle et al., 347 2021). This is in line with previous research showing an increase in mucin-degrading taxa, such 348 as *Escherichia-Shigella*, *Alistipes*, *Anaerostipes* (Di Lodovico et al., 2021; Glover et al., 2022) 349 and a reduction in butyrate producers, and an increase in carbohydrate (fiber)-degrading taxa 350 (Fouladi et al., 2022). In our longitudinal study, we failed to detect any major perturbation in a 351 352 butyrate-producing taxon (Singh et al., 2023).

Low-weight patients show a reduction in *Ruminococcus*, a well-known beneficial carbohydrate-fermenter commensal, whose abundance has increased in different studies as a consequence of increased fiber intake (Kleiman et al., 2015; Mack et al., 2016; Ruusunen et al., 2019). Underrepresented genera in the AN microbiome of low-weight patients include *Agathobacter* (also as reported by (Prochazkova et al., 2021; Yuan et al., 2022)) and

Romboustia (as in (Yuan et al., 2022)). Interestingly, some of the taxa that were overrepresented in patients at admission and in low-weight patients were the same and were reported to be higher in stunted children: Family XIII AD3011 group, uncl. Erysipelotrichaceae, and uncl. Ruminococcaceae (Golloso-Gubat et al., 2020).

After a 1-year follow-up, the family Desulfovibrionaceae remained altered even in the weight-recovered subgroup, with a relative abundance five times higher in recovered individuals than in HCs. These bacteria were shown to be associated with binge eating disorders in obese individuals (Navarro-Tapia et al., 2021), although they represent a rare taxon (less than 0.20% of the total microbiome) in our study, and it is thus difficult to disentangle their role in the gut-brain axis.

368 Importantly, the diminishing difference between HCs and recovered AN patients was 369 immediately offset in the case of a repeated weight loss. Low-weight patients showed renewed 370 dysbiosis at all taxonomic levels of similar magnitude as at admission. This emphasizes the 371 importance of maintaining a healthy target weight for regaining a healthy gut microbiome.

372 Clinical factors associated with gut microbiome

373 Interestingly, our analysis at admission showed that illness duration and weight loss were associated with alterations in the overall composition and structure of bacterial communities 374 375 within the group of adolescent patients with AN. To our knowledge, this is the first time that these two variables have been linked to the microbiome at admission. This is potentially 376 explained by the difference in age compared with adult patients, which is typically 377 accompanied by a difference in illness duration. Studying adolescents might have the 378 advantage of having a higher percentage of first-time ill patients with fewer compensatory or 379 treatment-related factors, allowing for a less confounded study of the original underlying 380 pathophysiology. Interestingly, the absolute low BMI-SDS did not reach significance cross-381 sectionally, which agrees with previous reports (Fan et al., 2023; Mack et al., 2016). However, 382

Di Lodovico (Di Lodovico et al., 2021) identified a correlation between *Roseburia* abundance and BMI. Borgo et al. (Borgo et al., 2017) highlighted a negative correlation of *Bacteroides* in adult samples, while Yuan et al. (Yuan et al., 2022) found *Subdoligranulum* was positively and *Bacteroides* was negatively associated with BMI in a mixed sample of adolescents and adults. This might be explained by differences in the statistical approach (PERMANOVA vs. univariate single taxa analyses) or by differences in age and illness duration.

389 Our longitudinal PERMANOVA analysis including genus-level data from all nine time points (adjusted for laxative use) helped address the question of which clinical parameters and 390 391 physiological changes during treatment were related to the changing gut microbiome. Indeed, we found that all three of our hypothesized factors (kilocalories consumed, achieved weight 392 gain, and hormonal recovery) were strongly related to changes in microbiome composition. 393 394 This is consistent with the previous clinical literature, which primarily underscores the influence of nutrition (David et al., 2014). It is interesting and important to demonstrate that it 395 is not purely nutritional rehabilitation that drives changes in the microbiome. Also, body weight 396 recovery was an important factor, potentially because of its link to an increase in fat mass, 397 normalization of metabolism and leaving behind the "emergency-state" of semi-starvation with 398 all its other metabolic counter-regulations to conserve energy. Finally, hormonal restitution, 399 studied using leptin concentration in the serum, showed an individually and independently 400 significant contribution. Leptin is an anorexigenic hormone secreted by fat cells and is known 401 402 to be severely reduced in acutely ill patients with AN and to recover with weight gain. It has numerous effects on metabolism, and its accommodation to starvation and leptin receptors is 403 found virtually throughout the human body (Hebebrand et al., 2022). Interestingly, it is known 404 to be both affected by (Yao et al., 2020) and to affect gut bacteria (Neuman et al., 2015), and 405 has recently been shown to be very promising as an experimental treatment in chronic patients 406 with AN (Gradl-Dietsch et al., 2023; Milos et al., 2020). 407

Taken together, these findings are important for understanding the underlying microbiome-gut-host interactions during AN. By identifying clinically relevant factors associated with microbiome changes, they added further validity to the relevance of the microbiome being linked to the severity and course of the disease.

412 Prognostic relevance of baseline microbiome for clinical outcome

After showing how clinical factors are associated with the microbiome in patients with AN, we 413 414 also investigated the potential influence of the microbiome on the course of illness. This is the first study to show that microbiome composition at admission is prognostically relevant for 415 hospital readmission within the first year. This shows the potential of microbiome analyses to 416 417 help clinicians in the prognosis of the clinical course and potentially divert more intense 418 resources to those most at risk. Interestingly, for most of the genera and taxa identified, a higher abundance was associated with a negative course (*Parasutterella*, *Clostridium sensu stricto*; 419 420 Lachnospiraceae FCS020 genera and uncultured Alistipes). Thus, the high abundance of these taxa should be regarded as a risk factor. Interestingly, a recent cross-sectional study on obesity 421 and type 1 diabetes reported the role of the genus *Parassuterella* in the stimulation of the 422 biosynthetic pathways of fatty acids, suggesting a role in body weight gain. Moreover, 423 Parassuterella was significantly reduced during weight loss interventions (Henneke et al., 424 425 2022). Clostridium sensu stricto 1 (also known as Clostridium cluster 1) levels were 22 times higher at admission than at follow-up in low-weight patients. Clostridium sensu stricto 1 is a 426 well-known mucin degrader that has been associated with AN, as this genus can induce a leaky 427 428 gut (Di Lodovico et al., 2021; Kleiman et al., 2015; Mack et al., 2016). Alistipes is known to be involved in depression, which highlights the multifactorial nature of AN (Parker et al., 429 430 2020). Members of the family *Lachnospiracea* are known to degrade carbohydrates to produce butyric acid and other SCFAs, which could help reduce inflammation (Yuan et al., 2022). 431 Decreased Lachnospiraceae is a well-accepted marker of inflammation in several 432

inflammatory disorders (Geirnaert et al., 2017; Maukonen & Ouwehand, 2022). Patients with
AN are thought to have chronic low-grade inflammation of unknown origin (meta-analysis by
(Dalton et al., 2018)); however, recent findings are more diverse and show variable
dysregulation of the immunologic state (Keeler et al., 2022; Schulz et al., 2021). AN is also
associated with an increased rate of autoimmune diseases, especially Crohn's disease and celiac
disease (Hedman et al., 2019; Raevuori et al., 2014). Therefore, the immunomodulatory effects
of these taxa might be important for their mechanistic role in AN outcomes.

In contrast, a higher Sutterella abundance at admission was associated with a positive 440 441 outcome of increased body weight after one year. Sutterella are commensals associated with a positive pro-inflammatory status (Hiippala et al., 2016). They are known to modulate 442 inflammatory processes; they decrease in multiple sclerosis and increase again after interferon 443 therapy (Giri & Mangalam, 2019). In a mouse obesity study, Sutterella was not found in high-444 fat diet-fed animals and only appeared after the introduction of prebiotic treatment, associated 445 with improved health (Everard et al., 2014). Due to the association of Sutterella with a positive 446 clinical course in our study, they might also be interesting candidates for probiotic 447 supplementation in Activity Based Anorexia (ABA)-animal models and patient studies. 448

These results complement our findings regarding clinical measures, such as illness 449 duration or weight loss, being intertwined with the gut microbiome at admission. One possible 450 interpretation is that the microbiome is initially influenced by food reduction and ensuing semi-451 starvation, fat mass reduction, and hormonal changes. Gut microbial changes could then exert 452 a causal, upholding influence favoring the maintenance of the disease, as transplantation 453 studies of stool of patients with ongoing AN into germ-free mice have shown reduced weight 454 455 gain as well as brain and behavioral changes in animals similar to those in AN (Fan et al., 2023; Hata et al., 2019). Whether the gut microbiome plays a role in the initial occurrence of AN 456 457 remains unclear and should be the target of future investigations.

Although this is one of the largest studies of patients with AN analyzing the 458 microbiome, larger samples are still required regarding the sheer number of taxa involved and 459 460 their potential interactions with each other and with the host. Furthermore, grouping patients at one year of admission together only on the basis of BMI is always somewhat artificial and 461 demonstrates the dire need for a more stringent definition of recovery from an eating disorder 462 including, for example, disordered eating behavior. Lastly, while longitudinal studies like ours 463 present a major advancement compared to purely cross-sectional studies, they still only allow 464 limited insight into causality and need to be supported by well-controlled interventional studies. 465

Taken together, we showed reduced, yet ongoing alterations in the gut microbiome after a 1-466 467 year follow-up, even in weight-recovered patients, and identified an important relationship between illness duration and weight loss with microbiome composition at admission and 468 provided evidence that kilocalories, body weight, and hormonal recovery are all associated 469 with the changing microbiome during treatment and weight gain. The microbiome at admission 470 has prognostic value for the course and outcome of the disease. Our results are consistent with 471 the hypothesis that changes in the body environment following semi-starvation influence the 472 composition of the gut microbiome. Together with transplantation data, our study further 473

supports the potential causal role of certain microbes, at least as maintaining factors prolonging
the disease. The role of the microbiome in the etiology of the initial phase of disease warrants
further investigation. Identifying taxa whose abundances are prognostic for the clinical course
could help stratify patients at admission and increase therapy intensity where most needed,
whereas *Sutterella* could potentially yield promising microbiome-targeted therapies as future
additions to existing AN treatment.

480 Patients and methods

481 **Recruitment**

Sixty-four female adolescents (aged between 12 and 20, mean16 years) diagnosed with typical 482 or atypical AN according to the DSM-5 were recruited at the Department for Child and 483 Adolescent Psychiatry of the RWTH Aachen University Hospital and enrolled between 484 December 2016 and January 2020. Seven patients dropped out of the study, leaving 57 patients 485 486 for the analysis. The inclusion criteria were the same as those previously published before (Schulz et al., 2021) with minor modifications: diagnosis of AN according to DSM 5, female 487 sex, and age between 12 and 20 years. The exclusion criteria were as follows: use of antibiotics 488 489 or probiotics within four weeks before enrollment, IO<85, insufficient knowledge of the German language, severe other mental disorders, and severe gastrointestinal or metabolic 490 illnesses such as celiac disease or diabetes mellitus. Stool samples collected within four weeks 491 492 of oral or intravenous antibiotic treatment were excluded from the analysis. Admission and discharge data for a subset of the current study (20 patients with AN and 20 HCs) have been 493 494 published previously (Schulz et al., 2021).

Additionally, 34 age-matched female HCs with normal body weight (>20th and <80th age adjusted percentile of body mass index [BMI-SDS]) were enrolled using newspaper advertisements. The same exclusion criteria as above were applied to HCs, in addition to any

498 current psychiatric illness or any lifetime eating disorder. All participants and their legal 499 guardians provided written informed consent prior to enrollment. Consent was obtained from 500 the ethics committee of the RWTH Aachen University Hospital for this study, and the study 501 was conducted in accordance with the Declaration of Helsinki.

502 Clinical data included height and body weight after an overnight fast at admission and 503 discharge, as well as weight and height prior to disease onset, weight loss prior to admission, 504 and illness duration. For all time points, BMI as well as age- and sex-specific BMI percentiles 505 and BMI-SDS were calculated based on German reference data from the KiGGS study 506 (Neuhauser et al., 2013). Any medication used at admission was noted and sorted into the 507 following groups for use as a binary covariate: laxatives, antibiotics, antidepressants, 508 gastrointestinal medications, and others.

509 Assessment timepoints

510 Up to nine time points were chosen for sampling (Fig 1): T0 (admission), T1 (corresponding to a diet of 25 Kcal/kg/day), T2 (corresponding to a diet of 50 Kcal/kg/day), T3 (corresponding 511 to a diet of 62.5 Kcal/kg/day), T4 (corresponding to a weight gain up to the 5th age-adjusted 512 BMI percentile), T5 (corresponding to a weight gain up to the 10th age-adjusted BMI 513 percentile), T6 (corresponding to a weight gain up to the 15th age-adjusted BMI percentile), T7 514 515 (discharge), and T8 (1-year follow-up appointment, one year after admission). Based on the clinical course, some patients reached more than one timepoint at a time and had fewer 516 sampling time points. Thirty-four HCs' samples were collected at six time points (T0, T2, T4, 517 518 T5, T7, and T8; Fig 1).

519 Questionnaires and interviews

Each participant in the study completed three questionnaires at admission, T2, T4, T5,
discharge, and 1-year follow-up appointment: The Eating Disorder Inventory 2 (EDI-2;

(Garner, 1991)), Beck Depression Inventory-II (BDI-II; (Kühner et al., 2007)) and Spence
Children's Anxiety Scale (SCAS; (Spence, 1998)). Patients also underwent semi-structured
EDE (Eating Disorder Examination, first German edition 2016; (Cooper & Fairburn, 1987;
Luce & Crowther, 1999)) at admission, discharge, and 1-year follow-up.

526 Fecal sample collection and DNA extraction

527 Fecal samples were collected as previously described (Schulz et al., 2021). Healthy volunteers 528 collected their stool at home using the same procedure and brought or sent the samples to the 529 clinic to be frozen at -80°C until further use. DNA extraction from stool samples was performed 530 using the DNeasy Power Soil Kit (Qiagen), following the manufacturer's instructions.

531 16S rRNA gene sequencing and processing

532 The V1-V2 region of the 16S rRNA gene was amplified with primers 27F and 338R using dual barcoding. During demultiplexing, no mismatches were allowed in the barcode (Casava, 533 534 Illumina). QIIME2 (v2019.10) was used to process and analyze the sequence data (Bolyen et 535 al., 2018). Paired end sequences were denoised with 'dada2' (Callahan et al., 2016) using default parameters, unless stated: reads were truncated at the first base where the quality score 536 dropped below Q=3, the maximum number of mismatches in the overlap region was 2, and the 537 538 minimum length of reads after truncation was 250 bp. Merged sequences were clustered into amplicon sequences variants (ASVs) using 'vsearch' with an identity of 0.97 (Rognes et al., 539 2016). Bacterial ASVs were annotated using the q2-feature-classifier plugin (Bokulich et al., 540 541 2018). The sequences were rarefied at 10,400 reads per sample.

542 Statistical analysis

All statistical analyses were performed using the R software (v. 4.1.1). Alpha-diversity within
samples (represented by the Shannon and Chao1 indices) was determined by applying the

estimate and diversity functions in "vegan" package (Oksanen & et al., 2022), while microbial 545 dissimilarities between samples (beta-diversity defined by Bray-Curtis dissimilarity) were 546 estimated at all taxonomic levels (phylum- to ASV- levels). Different time points of the HCs 547 were used in our analyses, and the first available time point (baseline T0) was used to compare 548 the microbiome compositions of HCs with those of patients with AN at admission (T0) and 549 discharge (T7). The last available time point for each HCs (usually after one year, T8) was used 550 551 for follow-up (T8) comparisons. We defined a 'core' microbiome as taxa that were present in at least 50% of individuals. 552

Analysis of gut microbiome in AN patients and healthy controls and longitudinal changes in the gut microbiome

555 We used multivariate and univariate methods to compare the microbiomes of patients at various taxonomic levels (from phylum- to ASV-level) with a) the microbiomes of the HC group and 556 557 b) those between different visits. To examine the differences in the overall microbiome composition between AN patients and the HC group at admission (T0), discharge (T7), and 558 follow-up (T8), we used permutational multivariate analysis of variance (PERMANOVA; 559 Anderson, 2017) implemented in the R package "vegan" (Oksanen et al., 2022) at all taxonomic 560 levels. In all the PERMANOVA models, the number of permutations was set to 10,000. In 561 562 order to determine which microbial taxa are primarily responsible for the differences between groups of samples, we performed partial least squares-discriminant analysis (PLS-DA), a 563 supervised multivariate dimensionality reduction and classification technique using the R 564 package "mixOmics" (Liquet et al., 2012; Rohart et al., 2017). Throughout our longitudinal 565 analyses, the dependence on multiple samples per individual at different visits was considered. 566 567 Therefore, to account for the clustering of samples by patients, we used the *strata* term in the adonis function to restrict the permutations within the samples from each patient for the 568 PERMANOVA models. Additionally, we used multilevel partial least squares-discriminant 569

analysis (mPLS-DA), which accounts for clustered samples (from the same patient) andcorrelations among microbial taxa.

After the PERMANOVA tests, non-parametric univariate tests were conducted at the taxonomic levels, where significant differences were observed to identify the taxa that contributed to those differences. We used Mann-Whitney-U-tests and Wilcoxon signed-rank tests for unpaired (patients vs. HCs) and paired (patients at different visits) respectively. The false discovery rate (fdr) approach was used to correct for multiple comparisons.

577 Analysis clinical variables associated with microbiome composition

PERMANOVA was also performed to examine the factors associated with microbiome 578 579 composition at the different visits. For each model, the effect of laxative use was corrected by 580 including it as the first independent variable. At T0, the association between microbiome composition and weight loss, illness duration, BMI-SDS, Kcal, and leptin was tested. We also 581 582 examined longitudinally the combined and individual effects of BMI-SDS and Kcal on the microbiome composition (genus-level) considering all visits together. Additionally, the 583 combined effects of BMI-SDS, leptin, and Kcal together and the effect of leptin alone 584 (unadjusted) on the microbiome composition were investigated longitudinally considering 585 visits T0, T7, and T8. 586

587 Analysis of prognostic relevance of baseline microbiome for clinical outcome

To investigate the association of the gut microbiota (genus- and ASV-levels) at admission (T0) or discharge (T7) with the different variables of clinical outcome (duration of treatment (only with admission microbiome), hospital readmission, and BMI-SDS at 1-year follow-up), first, a linear model (or logistic model for readmission) was constructed, where the effect of weight loss (calculated as the difference in BMI-SDS between disease onset (premorbid BMI-SDS) and admission to the clinic), duration of illness, and BMI-SDS at admission were regressed out

to control for factors known to influence the duration of inpatient treatment. Then, the residuals of this model were used as the dependent variable in a second linear model, with microbial relative abundances as an independent variable while controlling for laxative use. For the prediction analyses, we used the square root of the transformed relative abundances of the core microbial taxa to account for non-normal distributions.

599 Acknowledgements

The work was partly funded by the ERA-NET Neuron "Microbiome Gut Brain Axis in 600 Anorexia Nervosa (MiGBAN)" project sponsored by the European Union (EU) and the 601 German Ministry for Education and Research (BMBF) under Grant 01EW1906A; the Deutsche 602 Forschungsgemeinschaft (DFG) under the Grant SE 2787/3-1 ("The role of the intestinal 603 microbiome regarding prognosis and therapy in adolescent Anorexia nervosa - clinical and 604 translational analyses"); the Deutsche Forschungsgemeinschaft (DFG) Research Unit 605 FOR5042 under Grant DE1614/4-1 ("The microbiome as a therapeutic target in inflammatory 606 607 bowel diseases"); the Deutsche Forschungsgemeinschaft (DFG) Excellence Cluster under Grant EXC2167 ("Precision Medicine in Chronic 688 Inflammation PMI"). 608 The authors are grateful to Mrs. Katja Cloppenborg-Schmidt and Mrs. Yasmin Claußen for 609

610 their excellent technical support, and to the Clinical Trial Center Aachen (CTC-A) for their

611 support in conducting the study.

612 **Disclosure statement**

613 The authors report there are no competing interests to declare.

614 **Data availability statement**

615 Data available on request due to privacy/ethical restrictions.

616 Author contributions

- 517 JS, JB, and BHD designed the study; BD, HS, NM, VR, and JS recruited the participants and
- 618 helped gather clinical data and stool and blood samples; HS and LK oversaw sample logistics.
- 619 NA analyzed the stool samples; NA, AS, and AD performed statistical analyses. NA, AS, and
- 520 JS wrote the first draft of the manuscript. All coauthors revised the manuscript and agreed to
- 621 its publication.

622 **References**

- 623 Anderson, M. J. (2017). Permutational Multivariate Analysis of Variance (PERMANOVA). In N.
- 624 Balakrishnan, T. Colton, B. Everitt, W. Piegorsch, F. Ruggeri, & J. L. Teugels (Eds.), Wiley
- 625 *StatsRef: Statistics Reference Online* (1st ed., pp. 1–15). Wiley.
- 626 https://doi.org/10.1002/9781118445112.stat07841
- 627 Arcelus, J., Mitchell, A. J., Wales, J., & Nielsen, S. (2011). Mortality Rates in Patients With Anorexia
- 628 Nervosa and Other Eating Disorders: A Meta-analysis of 36 Studies. Archives of General
- 629 *Psychiatry*, 68(7), 724. https://doi.org/10.1001/archgenpsychiatry.2011.74
- 630 Bokulich, N. A., Kaehler, B. D., Rideout, J. R., Dillon, M., Bolyen, E., Knight, R., Huttley, G. A., &
- 631 Gregory Caporaso, J. (2018). Optimizing taxonomic classification of marker-gene amplicon

632 sequences with QIIME 2's q2-feature-classifier plugin. *Microbiome*, 6(1).

- 633 https://doi.org/10.1186/s40168-018-0470-z
- Bolyen, E., Rideout, J. R., Dillon, M., Bokulich, N., Abnet, C., Al-Ghalith, G., Alexander, H., Alm, E.,
- 635 Arumugam, M., Asnicar, F., Bai, Y., Bisanz, J., Bittinger, K., Brejnrod, A., Brislawn, C., Brown,
- 636 C. T., Callahan, B., Caraballo-Rodríguez, A. M., Chase, J., ... Caporaso, J. G. (2018). QIIME 2:
- 637 Reproducible, interactive, scalable, and extensible microbiome data science. *PeerJ*.
- 638 https://doi.org/10.7287/peerj.preprints.27295
- Borgo, F., Riva, A., Benetti, A., Casiraghi, M. C., Bertelli, S., Garbossa, S., Anselmetti, S., Scarone, S.,
- 640 Pontiroli, A. E., Morace, G., & Borghi, E. (2017). Microbiota in anorexia nervosa: The triangle
- 641 between bacterial species, metabolites and psychological tests. *PLOS ONE*, *12*(6), e0179739.
- 642 https://doi.org/10.1371/journal.pone.0179739
- Breton, J., Tirelle, P., Hasanat, S., Pernot, A., L'Huillier, C., do Rego, J.-C., Déchelotte, P., Coëffier, M.,
- 644 Bindels, L. B., & Ribet, D. (2021). Gut microbiota alteration in a mouse model of Anorexia
- 645 Nervosa. *Clinical Nutrition*, *40*(1), 181–189. https://doi.org/10.1016/j.clnu.2020.05.002
- Bulik, C. M., Flatt, R., Abbaspour, A., & Carroll, I. (2019). Reconceptualizing anorexia nervosa.
- 647 Psychiatry and Clinical Neurosciences, 73(9), 518–525. https://doi.org/10.1111/pcn.12857

- 648 Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016).
- 649 DADA2: High-resolution sample inference from Illumina amplicon data. *Nature Methods*,
- 650 *13*(7), 581–583. https://doi.org/10.1038/nmeth.3869
- 651 Carr, J., Kleiman, S. C., Bulik, C. M., Bulik-Sullivan, E. C., & Carroll, I. M. (2016). Can attention to the
- 652 intestinal microbiota improve understanding and treatment of anorexia nervosa? *Expert*
- 653 *Review of Gastroenterology & Hepatology, 10*(5), 565–569.
- 654 https://doi.org/10.1586/17474124.2016.1166953
- 655 Cooper, Z., & Fairburn, C. (1987). The eating disorder examination: A semi-structured interview for
- the assessment of the specific psychopathology of eating disorders. *International Journal of*
- 657 *Eating Disorders, 6*(1), Article 1.
- Dalton, B., Bartholdy, S., Robinson, L., Solmi, M., Ibrahim, M. A., Breen, G., Schmidt, U., &
- Himmerich, H. (2018). A meta-analysis of cytokine concentrations in eating disorders.
 Journal of Psychiatric Research.
- David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V.,
- 662 Devlin, A. S., Varma, Y., Fischbach, M. A., Biddinger, S. B., Dutton, R. J., & Turnbaugh, P. J.
- 663 (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature*, 505(7484),
- 664 Article 7484. https://doi.org/10.1038/nature12820
- 665 Dhopatkar, N., Keeler, J. L., Mutwalli, H., Whelan, K., Treasure, J., & Himmerich, H. (2023).
- 666 Gastrointestinal symptoms, gut microbiome, probiotics and prebiotics in anorexia nervosa: A
- 667 review of mechanistic rationale and clinical evidence. *Psychoneuroendocrinology*, 147,
- 668 105959. https://doi.org/10.1016/j.psyneuen.2022.105959
- 669 Di Lodovico, L., Mondot, S., Doré, J., Mack, I., Hanachi, M., & Gorwood, P. (2021). Anorexia nervosa
- 670 and gut microbiota: A systematic review and quantitative synthesis of pooled
- 671 microbiological data. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 106,
- 672 110114. https://doi.org/10.1016/j.pnpbp.2020.110114

673 Everard, A., Lazarevic, V., Gaïa, N., Johansson, M., Ståhlman, M., Backhed, F., Delzenne, N. M.,

- 674 Schrenzel, J., François, P., & Cani, P. D. (2014). Microbiome of prebiotic-treated mice reveals
- 675 novel targets involved in host response during obesity. *The ISME Journal*, 8(10), 2116–2130.
- 676 https://doi.org/10.1038/ismej.2014.45
- 677 Fan, Y., Støving, R. K., Berreira Ibraim, S., Hyötyläinen, T., Thirion, F., Arora, T., Lyu, L., Stankevic, E.,
- 678 Hansen, T. H., Déchelotte, P., Sinioja, T., Ragnarsdottir, O., Pons, N., Galleron, N., Quinquis,
- 679 B., Levenez, F., Roume, H., Falony, G., Vieira-Silva, S., ... Pedersen, O. (2023). The gut
- 680 microbiota contributes to the pathogenesis of anorexia nervosa in humans and mice. *Nature*
- 681 *Microbiology*. https://doi.org/10.1038/s41564-023-01355-5
- 682 Fouladi, F., Bulik-Sullivan, E. C., Glenny, E. M., Thornton, L. M., Reed, K. K., Thomas, S., Kleiman, S.,

683 Watters, A., Oakes, J., Huh, E.-Y., Tang, Q., Liu, J., Djukic, Z., Harper, L., Trillo-Ordoñez, Y.,

- 684 Sun, S., Blakely, I., Mehler, P. S., Fodor, A. A., ... Carroll, I. M. (2022). Reproducible changes in
- 685 the anorexia nervosa gut microbiota following inpatient therapy remain distinct from non-
- 686 eating disorder controls. *Gut Microbes*, *14*(1), 2143217.
- 687 https://doi.org/10.1080/19490976.2022.2143217
- 688 Garcia, N., & Gutierrez, E. (2023). Anorexia nervosa and microbiota: Systematic review and critical
- 689 appraisal. Eating and Weight Disorders Studies on Anorexia, Bulimia and Obesity, 28(1), 1.

690 https://doi.org/10.1007/s40519-023-01529-4

691 Garcia-Gil, M., Ceccarini, M. R., Stoppini, F., Cataldi, S., Mazzeschi, C., Delvecchio, E., Albi, E., & Gizzi,

692 G. (2022). Brain and gut microbiota disorders in the psychopathology of anorexia nervosa.

- 693 *Translational Neuroscience*, *13*(1), 516–526. https://doi.org/10.1515/tnsci-2022-0267
- 694 Garner, D. M. (1991). *Eating disorder inventory-2*.
- 695 Geirnaert, A., Calatayud, M., Grootaert, C., Laukens, D., Devriese, S., Smagghe, G., De Vos, M., Boon,
- 696 N., & Van de Wiele, T. (2017). Butyrate-producing bacteria supplemented in vitro to Crohn's
- 697 disease patient microbiota increased butyrate production and enhanced intestinal epithelial

698	barrier integrity. Scientific Reports,	7(1), Article 1. https	s://doi.org/10.1038/s41598-017-
-----	--	------------------------	---------------------------------

699 11734-8

- Giri, S., & Mangalam, A. (2019). The Gut Microbiome and Metabolome in Multiple Sclerosis. In
- 701 *Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications* (pp.
- 702 333–340). Elsevier. https://doi.org/10.1016/B978-0-12-815249-2.00034-8
- 703 Glover, J. S., Ticer, T. D., & Engevik, M. A. (2022). Characterizing the mucin-degrading capacity of the
- human gut microbiota. *Scientific Reports*, 12(1), 8456. https://doi.org/10.1038/s41598-022-
- 705 11819-z
- Golloso-Gubat, M. J., Ducarmon, Q. R., Tan, R. C. A., Zwittink, R. D., Kuijper, E. J., Nacis, J. S., &
- 707 Santos, N. L. C. (2020). Gut Microbiota and Dietary Intake of Normal-Weight and Overweight
- 708Filipino Children. Microorganisms, 8(7), 1015.
- 709 https://doi.org/10.3390/microorganisms8071015
- 710 Gradl-Dietsch, G., Milos, G., Wabitsch, M., Bell, R., Tschöpe, F., Antel, J., & Hebebrand, J. (2023).
- 711 Rapid Emergence of Appetite and Hunger Resulting in Weight Gain and Improvement of
- 712 Eating Disorder Symptomatology during and after Short-Term Off-Label Metreleptin
- 713 Treatment of a Patient with Anorexia Nervosa. *Obesity Facts*, *16*(1), 99–107.
- 714 https://doi.org/10.1159/000527386
- Hata, T., Miyata, N., Takakura, S., Yoshihara, K., Asano, Y., Kimura-Todani, T., Yamashita, M., Zhang,
- 716 X.-T., Watanabe, N., Mikami, K., Koga, Y., & Sudo, N. (2019). The Gut Microbiome Derived
- 717 From Anorexia Nervosa Patients Impairs Weight Gain and Behavioral Performance in Female
- 718 Mice. Endocrinology, 160(10), Article 10. https://doi.org/10.1210/en.2019-00408
- Hebebrand, J., Hildebrandt, T., Schlögl, H., Seitz, J., Denecke, S., Vieira, D., Gradl-Dietsch, G., Peters,
- 720 T., Antel, J., Lau, D., & Fulton, S. (2022). The role of hypoleptinemia in the psychological and
- 721 behavioral adaptation to starvation: Implications for anorexia nervosa. Neuroscience &
- 722 Biobehavioral Reviews, 141, 104807. https://doi.org/10.1016/j.neubiorev.2022.104807

723 Incumul, Λ_{i} Dicitizity, E_{i} Hubel, C_{i} Hibiniton, E_{i} Mi, Hibiniton, Λ_{i} Northig, C_{i} Digesu	L., Hübel, C., Thornton, L. M., Tillander, A., Norring, C., Bi	rgegård, A
---	--	------------

- 724 Larsson, H., Ludvigsson, J. F., Sävendahl, L., Almqvist, C., & Bulik, C. M. (2019). Bidirectional
- relationship between eating disorders and autoimmune diseases. *Journal of Child Psychology*

726 and Psychiatry, 60(7), 803–812. https://doi.org/10.1111/jcpp.12958

- Henneke, L., Schlicht, K., Andreani, N. A., Hollstein, T., Demetrowitsch, T., Knappe, C., Hartmann, K.,
- Jensen-Kroll, J., Rohmann, N., Pohlschneider, D., Geisler, C., Schulte, D. M., Settgast, U., Türk,
- 729 K., Zimmermann, J., Kaleta, C., Baines, J. F., Shearer, J., Shah, S., ... Laudes, M. (2022). A
- 730 *dietary carbohydrate gut Parasutterella human fatty acid biosynthesis* metabolic axis in
- 731 obesity and type 2 diabetes. *Gut Microbes*, *14*(1), 2057778.
- 732 https://doi.org/10.1080/19490976.2022.2057778
- Herpertz-Dahlmann, B., Bonin, E., & Dahmen, B. (2021). Can you find the right support for children,
- adolescents and young adults with anorexia nervosa: Access to age-appropriate care
- 735 systems in various healthcare systems. *European Eating Disorders Review*, *29*(3), 316–328.

736 https://doi.org/10.1002/erv.2825

- Hiippala, K., Kainulainen, V., Kalliomäki, M., Arkkila, P., & Satokari, R. (2016). Mucosal Prevalence and
- 738 Interactions with the Epithelium Indicate Commensalism of Sutterella spp. Frontiers in
- 739 *Microbiology*, 7. https://doi.org/10.3389/fmicb.2016.01706
- Hills, R. D., Pontefract, B. A., Mishcon, H. R., Black, C. A., Sutton, S. C., & Theberge, C. R. (2019). Gut
- 741 microbiome: Profound implications for diet and disease. *Nutrients*, *11*(7).
- 742 https://doi.org/10.3390/nu11071613
- 743 Kaur, H., Bose, C., & Mande, S. S. (2019). Tryptophan Metabolism by Gut Microbiome and Gut-Brain-
- 744 Axis: An in silico Analysis. *Frontiers in Neuroscience*, *13*, 1365.
- 745 https://doi.org/10.3389/fnins.2019.01365
- 746 Keeler, J. L., Treasure, J., Juruena, M. F., Kan, C., & Himmerich, H. (2022). Reply to Skokou, M.
- 747 Comment on "Keeler et al. Ketamine as a Treatment for Anorexia Nervosa: A Narrative

748 Review. Nutrients 2021, 13, 4158." *Nutrients*, 14(10), 2119.

- 749 https://doi.org/10.3390/nu14102119
- 750 Kleiman, S. C., Watson, H. J., Bulik-Sullivan, E. C., Huh, E. Y., Tarantino, L. M., Bulik, C. M., & Carroll, I.
- 751 M. (2015). The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment:
- 752 Relationship to Depression, Anxiety, and Eating Disorder Psychopathology. *Psychosomatic*

753 *Medicine*, 77(9), 969–981. https://doi.org/10.1097/PSY.00000000000247

- 754 Kühner, C., Bürger, C., Keller, F., & Hautzinger, M. (2007). Reliabilität und Validität des revidierten
- 755 Beck-Depressionsinventars (BDI-II). *Der Nervenarzt*, 78(6), Article 6.
- 756 https://doi.org/10.1007/s00115-006-2098-7
- 757 Leyrolle, Q., Cserjesi, R., Mulders, M. D. G. H., Zamariola, G., Hiel, S., Gianfrancesco, M. A., Rodriguez,
- J., Portheault, D., Amadieu, C., Leclercq, S., Bindels, L. B., Neyrinck, A. M., Cani, P. D.,
- 759 Karkkainen, O., Hanhineva, K., Lanthier, N., Trefois, P., Paquot, N., Cnop, M., ... Delzenne, N.
- 760 M. (2021). Specific gut microbial, biological, and psychiatric profiling related to binge eating
- 761 disorders: A cross-sectional study in obese patients. *Clinical Nutrition*, 40(4), 2035–2044.
- 762 https://doi.org/10.1016/j.clnu.2020.09.025
- 763 Liquet, B., Cao, K.-A. L., Hocini, H., & Thiébaut, R. (2012). A novel approach for biomarker selection
- and the integration of repeated measures experiments from two assays. BMC

765 Bioinformatics, 13(1), 325. https://doi.org/10.1186/1471-2105-13-325

- Luce, K. H., & Crowther, J. H. (1999). The reliability of the eating disorder examination?Self-report
 questionnaire version (EDE-Q). *International Journal of Eating Disorders*, *25*(3), 349–351.
- 768 https://doi.org/10.1002/(SICI)1098-108X(199904)25:3<349::AID-EAT15>3.0.CO;2-M
- 769 Mack, I., Cuntz, U., Grämer, C., Niedermaier, S., Pohl, C., Schwiertz, A., Zimmermann, K., Zipfel, S.,
- 770 Enck, P., & Penders, J. (2016). Weight gain in anorexia nervosa does not ameliorate the
- faecal microbiota, branched chain fatty acid profiles and gastrointestinal complaints.
- 772 Scientific Reports, 6(1), 26752. https://doi.org/10.1038/srep26752

- 773 Mason, B. L., Li, Q., Minhajuddin, A., Czysz, A. H., Coughlin, L. A., Hussain, S. K., Koh, A. Y., & Trivedi,
- 774 M. H. (2020). Reduced anti-inflammatory gut microbiota are associated with depression and
- anhedonia. *Journal of Affective Disorders*, 266, 394–401.
- 776 https://doi.org/10.1016/j.jad.2020.01.137
- 777 Maukonen, J., & Ouwehand, A. C. (2022). Changes in the Microbiota Composition and Function in
- 778 Relation to Aging. In *Comprehensive Gut Microbiota* (pp. 85–96). Elsevier.

779 https://doi.org/10.1016/B978-0-12-819265-8.00060-7

- 780 Milos, G., Antel, J., Kaufmann, L.-K., Barth, N., Koller, A., Tan, S., Wiesing, U., Hinney, A., Libuda, L.,
- 781 Wabitsch, M., von Känel, R., & Hebebrand, J. (2020). Short-term metreleptin treatment of
- 782 patients with anorexia nervosa: Rapid on-set of beneficial cognitive, emotional, and
- behavioral effects. *Translational Psychiatry*, *10*(1), 303. https://doi.org/10.1038/s41398-02000977-1
- 785 Monteleone, A. M., Troisi, J., Serena, G., Fasano, A., Dalle Grave, R., Cascino, G., Marciello, F., Calugi,
- 786 S., Scala, G., Corrivetti, G., & Monteleone, P. (2021). The Gut Microbiome and Metabolomics
- 787 Profiles of Restricting and Binge-Purging Type Anorexia Nervosa. *Nutrients*, 13(2), 507.
- 788 https://doi.org/10.3390/nu13020507
- 789 Navarro-Tapia, E., Almeida-Toledano, L., Sebastiani, G., Serra-Delgado, M., García-Algar, Ó., &
- 790 Andreu-Fernández, V. (2021). Effects of Microbiota Imbalance in Anxiety and Eating
- 791 Disorders: Probiotics as Novel Therapeutic Approaches. International Journal of Molecular

792 *Sciences*, *22*(5), 2351. https://doi.org/10.3390/ijms22052351

- 793 Neuhauser, H., Schienkiewitz, A., Schaffrath Rosario, A., Dortschy, R., & Kurth, B.-M. (2013).
- 794 Referenzperzentile für anthropometrische Maßzahlen und Blutdruck aus der Studie zur
 795 Gesundheit von Kindern und Jugendlichenin Deutschland (KiGGS). RKI-Hausdruckerei.
- 796 Neuman, H., Debelius, J. W., Knight, R., & Koren, O. (2015). Microbial endocrinology: The interplay
- 797 between the microbiota and the endocrine system. *FEMS Microbiology Reviews*, *39*(4),
- 798 Article 4. https://doi.org/10.1093/femsre/fuu010

799 Oksanen, J., & et al. (2022). Vegan: Community Ecology Package. R package version 2.6-4.

- 800 https://github.com/vegandevs/vegan
- 801 Parker, B. J., Wearsch, P. A., Veloo, A. C. M., & Rodriguez-Palacios, A. (2020). The Genus Alistipes:
- 802 Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health.
- 803 *Frontiers in Immunology, 11,* 906. https://doi.org/10.3389/fimmu.2020.00906
- Pfleiderer, A., Mishra, A. K., Lagier, J.-C., Robert, C., Caputo, A., Raoult, D., & Fournier, P.-E. (2014).
- 805 Non-contiguous finished genome sequence and description of Alistipes ihumii sp. Nov.
- 806 Standards in Genomic Sciences, 9(3), 1221–1235. https://doi.org/10.4056/sigs.4698398
- 807 Prochazkova, P., Roubalova, R., Dvorak, J., Kreisinger, J., Hill, M., Tlaskalova-Hogenova, H.,
- 808 Tomasova, P., Pelantova, H., Cermakova, M., Kuzma, M., Bulant, J., Bilej, M., Smitka, K.,
- Lambertova, A., Holanova, P., & Papezova, H. (2021). The intestinal microbiota and
- 810 metabolites in patients with anorexia nervosa. *Gut Microbes*, *13*(1), 1902771.
- 811 https://doi.org/10.1080/19490976.2021.1902771
- 812 Raevuori, A., Haukka, J., Vaarala, O., Suvisaari, J. M., Gissler, M., Grainger, M., Linna, M. S., & Suokas,
- J. T. (2014). The increased risk for autoimmune diseases in patients with eating disorders.
- 814 *PloS One, 9*(8), Article 8. https://doi.org/10.1371/journal.pone.0104845
- Rognes, T., Flouri, T., Nichols, B., Quince, C., & Mahé, F. (2016). VSEARCH: A versatile open source
 tool for metagenomics. *PeerJ*, *2016*(10). https://doi.org/10.7717/peerj.2584
- 817 Rohart, F., Gautier, B., Singh, A., & Cao, K.-A. L. (2017). mixOmics: An R package for 'omics feature
- selection and multiple data integration. *PLOS Computational Biology*, *13*(11), e1005752.
- 819 https://doi.org/10.1371/journal.pcbi.1005752
- 820 Ruusunen, A., Rocks, T., Jacka, F., & Loughman, A. (2019). The gut microbiome in anorexia nervosa:
- 821 Relevance for nutritional rehabilitation. *Psychopharmacology*, *236*(5), 1545–1558.
- 822 https://doi.org/10.1007/s00213-018-5159-2

023 $30110000, E., Maii, 7., Charles, 1.7., Hakin Chia, N., C. 1001, 5. (2021). Carteric knowledge a$	e about
---	---------

- 824 the connection between health status and gut microbiota from birth to elderly. A narrative
- 825 review. Frontiers in Bioscience-Landmark, 26(6), 135. https://doi.org/10.52586/4930
- Schulz, N., Belheouane, M., Dahmen, B., Ruan, V. A., Specht, H. E., Dempfle, A., Herpertz-Dahlmann,
- 827 B., Baines, J. F., & Seitz, J. (2021). Gut microbiota alteration in adolescent anorexia nervosa
- 828 does not normalize with short-term weight restoration. *International Journal of Eating*
- 829 Disorders, 54(6), 969–980. https://doi.org/10.1002/eat.23435
- 830 Seitz, J., Dahmen, B., Keller, L., & Herpertz-Dahlmann, B. (2020). Gut Feelings: How Microbiota Might
- 831 Impact the Development and Course of Anorexia Nervosa. *Nutrients*, *12*(11), 3295.
- 832 https://doi.org/10.3390/nu12113295
- Singh, V., Lee, G., Son, H., Koh, H., Kim, E. S., Unno, T., & Shin, J.-H. (2023). Butyrate producers, "The
- 834 Sentinel of Gut": Their intestinal significance with and beyond butyrate, and prospective use 835 as microbial therapeutics. *Frontiers in Microbiology*, *13*, 1103836.

836 https://doi.org/10.3389/fmicb.2022.1103836

- Spence, S. H. (1998). A measure of anxiety symptoms among children. *Behaviour Research and Therapy*, *36*(5), Article 5.
- 839 Tennoune, N., Chan, P., Breton, J., Legrand, R., Chabane, Y. N., Akkermann, K., Jarv, A., Ouelaa, W.,
- 840 Takagi, K., Ghouzali, I., Francois, M., Lucas, N., Bole-Feysot, C., Pestel-Caron, M., do Rego, J.-
- 841 C., Vaudry, D., Harro, J., De, E., Dechelotte, P., & Fetissov, S. O. (2014). Bacterial ClpB heat-
- 842 shock protein, an antigen-mimetic of the anorexigenic peptide alpha-MSH, at the origin of
- 843 eating disorders. *Translational Psychiatry*, *4*, e458. https://doi.org/10.1038/tp.2014.98
- Trinh, S., Kogel, V., Voelz, C., Schlösser, A., Schwenzer, C., Kabbert, J., Heussen, N., Clavel, T.,
- 845 Herpertz-Dahlmann, B., Beyer, C., & Seitz, J. (2021). Gut microbiota and brain alterations in a
- 846 translational anorexia nervosa rat model. *Journal of Psychiatric Research*, *133*, 156–165.
- 847 https://doi.org/10.1016/j.jpsychires.2020.12.030

- 848 Wu, Y., Wang, C.-Z., Wan, J.-Y., Yao, H., & Yuan, C.-S. (2021). Dissecting the Interplay Mechanism
- 849 between Epigenetics and Gut Microbiota: Health Maintenance and Disease Prevention.
- 850 International Journal of Molecular Sciences, 22(13), 6933.
- 851 https://doi.org/10.3390/ijms22136933
- Yao, H., Fan, C., Fan, X., Lu, Y., Wang, Y., Wang, R., Tang, T., & Qi, K. (2020). Effects of gut microbiota
- 853 on leptin expression and body weight are lessened by high-fat diet in mice. *British Journal of*
- 854 Nutrition, 124(4), 396–406. https://doi.org/10.1017/S0007114520001117
- Yuan, R., Yang, L., Yao, G., Geng, S., Ge, Q., Bo, S., & Li, X. (2022). Features of gut microbiota in
- patients with anorexia nervosa. *Chinese Medical Journal*, *135*(16), 1993–2002.
- 857 https://doi.org/10.1097/CM9.00000000002362

859 Tables

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		AN admission	AN discharge	AN 1 year (P<15)	AN 1 year $(P \ge 15)$	HC baseline	HC 1 year
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Ν	57	50	19	25	34	34
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		16.07 (1.86)	16.34 (1.77)	17.27 (1.54)	16.62 (1.99)	16.44 (1.06)	17.48 (1.08)
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Age (years)	[12; 20.35]	[12.23; 19.01]	[14.21; 19.34]	[13.10; 19.84]	[14.11; 18.46]	[15.05; 19.42]
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	PMI (K_{α}/m^2)	15.88 (1.75)	18.94 (0.95)	17.94 (0.95)	19.86 (1.21)	21.06 (1.98)	21.59 (2.15)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Biiii (Kg/iii)	[12.50; 18.77]	[16.85; 20.96]	[15.85; 19.28]	[17.09; 21.93]	[17.65; 26.07]	[17.82; 25.94]
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	0/ EDW	75.09 (8.41)	89.05 (4.14)	83.01 (4.07)	93.02 (4.49)	98.19 (9.26)	99.33 (10.04)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	%EBW	[56.95; 87.74]	[77.59; 97.25]	[73.57; 87.84]	[86.93; 104.04]	[84.48; 122.00]	[84.22; 124.04]
BMI-SDS (Z-score) [-8.08; -0.93] [-2.44; -0.20] [-2.95; -1.07] [-1.06; 0.25] [-1.30; 1.15] [-1.37; 1.20] Premorbid BMI (kg/ m ²) 19.73 (2.78) [13.01; 26.60] [-1.30; 1.05] [-1.30; 1.15] [-1.37; 1.20] Premorbid BMI-SDS (z-score) -0.43 (1.04) [-4.24; 1.21] [-1.37; 1.20] [-1.30; 1.15] [-1.37; 1.20] Illness duration (month) 17.66 (14.340) [1.63; 71.97] [-1.37; 1.20] [-1.30; 1.15] [-1.37; 1.20] EDI 2 total score 297.2 (58.91) [158; 428] [127; 415] [156; 351] [166; 392] [128; 236] [133; 253] PDI W 24.29 (11.70) 19.28 (13.35) 17.95 (13.36) 16.4 (12.66) 4.85 (4.17) 4.97 (3.46)	DMI SDS ()	-2.92 (1.69)	-0.94 (0.46)	-1.66 (0.57)	-0.56 (0.37)	-0.22 (0.64)	-0.15 (0.70)
Premorbid BMI (kg/ m²) 19.73 (2.78) [13.01; 26.60] Image: Constraint of the system of	BMI-SDS (z-score)	[-8.08; -0.93]	[-2.44; -0.20]	[-2.95; -1.07]	[-1.06; 0.25]	[-1.30; 1.15]	[-1.37; 1.20]
Premorbid BMI (kg/m ⁻) [13.01; 26.60]	Denor and it DML (los / m ²)	19.73 (2.78)					
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Premorbid BMI (kg/m ⁻)	[13.01; 26.60]					
Premorbid BMI-SDS (Z-score) [-4.24; 1.21] Image: Constraint of the state of th	Deneration DML CDC (= +++++)	-0.43 (1.04)					
Illness duration (month) 17.66 (14.340) [1.63; 71.97] Image: Constraint of the system	Premorbid BMI-SDS (Z-score)	[-4.24; 1.21]					
Inness duration (month) [1.63; 71.97] 285.80 (62.92) 281.47 (50.64) 266.28 (60.45) 182.64 (29.57) 182.85 (31.77) EDI 2 total score 297.2 (58.91) 285.80 (62.92) 281.47 (50.64) 266.28 (60.45) 182.64 (29.57) 182.85 (31.77) [158; 428] [127; 415] [156; 351] [166; 392] [128; 236] [133; 253] DEM M 24.29 (11.70) 19.28 (13.35) 17.95 (13.36) 16.4 (12.66) 4.85 (4.17) 4.97 (3.46)	Illusion dometical (magnetic)	17.66 (14.340)					
EDI 2 total score 297.2 (58.91) [158; 428] 285.80 (62.92) [127; 415] 281.47 (50.64) [156; 351] 266.28 (60.45) [166; 392] 182.64 (29.57) [128; 236] 182.85 (31.77) [133; 253] DDL H 24.29 (11.70) 19.28 (13.35) 17.95 (13.36) 16.4 (12.66) 4.85 (4.17) 4.97 (3.46)	filness duration (month)	[1.63; 71.97]					
EDI 2 total score [158; 428] [127; 415] [156; 351] [166; 392] [128; 236] [133; 253] DDL H 24.29 (11.70) 19.28 (13.35) 17.95 (13.36) 16.4 (12.66) 4.85 (4.17) 4.97 (3.46)	EDI 2 total com	297.2 (58.91)	285.80 (62.92)	281.47 (50.64)	266.28 (60.45)	182.64 (29.57)	182.85 (31.77)
DD1 24.29 (11.70) 19.28 (13.35) 17.95 (13.36) 16.4 (12.66) 4.85 (4.17) 4.97 (3.46)	EDI 2 total score	[158; 428]	[127; 415]	[156; 351]	[166; 392]	[128; 236]	[133; 253]
		24.29 (11.70)	19.28 (13.35)	17.95 (13.36)	16.4 (12.66)	4.85 (4.17)	4.97 (3.46)
[0; 47] [0; 54] [0; 44] [0; 53] [0; 17] [0; 11]	BDI-II score	[0; 47]	[0; 54]	[0; 44]	[0; 53]	[0; 17]	[0; 11]
33 (18.18) 28.10 (18.03) 22.84 (14.32) 25.4 (18.64) 16.33 (7.18) 14.68 (6.89)	SCAS total array	33 (18.18)	28.10 (18.03)	22.84 (14.32)	25.4 (18.64)	16.33 (7.18)	14.68 (6.89)
SCAS total score [2; 77] [0; 75] [1; 51] [2; 67] [4: 34] [2; 31]	SUAS total score	[2; 77]	[0; 75]	[1; 51]	[2; 67]	[4; 34]	[2; 31]
3.22 (1.55) 3.38 (1.40) 3.88 (1.47) 3.30 (1.78)	EDE	3.22 (1.55)	3.38 (1.40)	3.88 (1.47)	3.30 (1.78)		
EDE mean [0.42; 5.4] [0.62; 5.32] [1.45; 5.33] [0.19; 5.24]	EDE mean	[0.42; 5.4]	[0.62; 5.32]	[1.45; 5.33]	[0.19; 5.24]		

860 Table 1: Clinical sample characteristics.

861

Values are reported as the mean and standard deviation in brackets, and minimum and
maximum values in square brackets. Abbreviations: AN, Anorexia Nervosa; BDI, Beck
Depression Inventory; BMI-SDS, Body mass index-standard deviation score; EDE, Eating
Disorder Examination; EDI, Eating Disorder Inventory; HC, Healthy Controls; SCAS, Spence
Children's Anxiety Scale; %EBW: Percent expected body weight.

868 Figures

869 *Figure 1: overview of the longitudinal study*



871 Figure 2: clinical information of the patients and age-matched healthy controls



873 Figure 3: the microbiome of patients changes during inpatient treatment and differs from

874 *HCs*





876 Figure 4: microbiome differences of patients at different timepoints and HC group



877

Figure 5: clinical variables that are associated with microbiome composition



Figure 6: taxa predicting BMI-SDS at 1-year follow-up



884 Fig S1: comparison of the microbiome of patients at admission/discharge and age-matched

885 *healthy*

controls



887 Figure captions

888 Figure 1: overview of the longitudinal study

889 This figure summarizes the samples used in this study, where n refers to the number of890 individuals included at each time point.

891 Figure 2: clinical information of the patients and age-matched healthy controls

The figure reports: (**A**) the amount of daily caloric intake of patients before admission, during inpatient treatment, and at follow-up appointment (1 year after admission), compared to HCs at baseline and at 1 year; (**B**) the BMI-SDS of patients before disease onset, during inpatient treatment, and at follow-up appointment (1 year after admission), compared to HCs at baseline and at 1 year; and (**C**) the serum concentration of leptin (ng/ml) of patients at admission, discharge, and at follow-up appointment (1 year after admission), compared to HCs at admission and at 1 year.

Figure 3: the microbiome of patients changes during inpatient treatment and differs from HCs

The figure reports: (A) the average relative abundance of 23 genera that were significantly 901 differentially abundant in univariate pairwise comparisons of patients at different time points 902 (T0, T7, and T8), and of healthy controls at baseline and 1 year. Stars at T0 admission report 903 904 the main genera that have significantly higher abundance in fecal samples of patients at admission than in the respective HCs. For other pairwise comparisons, please refer to 905 supplementary tables. (B) Multilevel PLS-DA of microbiome composition of patients at all 906 907 time points; (C) Boxplots of alpha-diversity measures, Shannon Index (left), and Chao1 Index (right) of patients' microbiome at different time points and of healthy controls. Groups depicted 908 with the same letter show no significant differences when pairwise comparisons are performed. 909

910 Figure 4: microbiome differences of patients at different timepoints and HC group

The figure reports: (**A**) a summary of the results of PERMANOVA test on Bray Curtis dissimilarities between patients and HCs, or between patients at different time points (n.s: pvalue>0.05; *: p-value <0.01; **: p-value <0.001; ***: p-value <0.0001). Details are reported in Tab S1_Sheet4; (**B**) PLS-DA plots highlighting differences at the genus level between HCs at baseline and patients at admission, (**C**) at discharge, (**D**) and differences at the genus level between patients at the 1-year follow-up (divided into low-weight and recovered) and HCs at the 1-year follow-up.

- 918 Figure 5: clinical variables that are associated with microbiome composition
- 919 n.s: p-value>0.05; *: p-value <0.01; **: p-value <0.001; ***: p-value <0.0001
- 920 Figure 6: taxa predicting BMI-SDS at 1-year follow-up
- Association of specific taxa at admission (T0) with BMI-SDS at 1-year follow-up, adjusted for
 weight loss (before admission), duration of illness, BMI-SDS at admission, and laxative use
 (see Patients and Methods for details on statistical models).
- 924 Fig S1: comparison of the microbiome of patients at admission/discharge and age-matched
 925 healthy controls
- The figure reports the genera that mostly contribute to the discrimination of patients at admission (**A**) or discharge (**B**) and the HC group, and of patients at 1-year follow-up (divided into low-weight and recovered) and HCs (**C**). Figure (**D**) shows the PLS-DA plot highlighting differences at the genus-level between recovered patients and the HC group. (**E**) The PLS-DA plot highlighting differences at the genus-level between low-weight patients and the HC group. The genera that mostly contributed to the discrimination are shown on the right side of each figure.
- 933